Mycophenolate Mofetil

Abstract

Pharmacoeconomic studies support the use of mycophenolate mofetil as part of immunosuppressant therapy in renal transplantation, at least in the short term. Although the cost effectiveness of mycophenolate mofetil in the long term is less clear, limited pharmacoeconomic data available appear promising. Among issues to be examined in future economic analyses in renal transplantation are the calcineurin-sparing potential of mycophenolate mofetil and the feasibility of using more efficient mycophenolate mofetil dosage regimens when using the drug on a long-term basis. Additional pharmacoeconomic analyses of mycophenolate mofetil are also needed in other types of solid organ transplantation.

The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?

“…A pharmacoeconomic review of studies in solid organ transplant recipients conducted within and outside the United States showed a cost benefit for MMF in the short term, postulating similar outcomes likely long term. These factors have offset the higher drug acquisition cost of MMF so that short term costs are equivalent or cost saving when compared to azathioprine (24). Most studies associate MMF with lower treatment costs and associated hospital admissions due to reduced incidence and severity of rejection episodes.…”